

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET

Fagron completes share buy-back program

In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its own shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00.

A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00.

The share buy-back program was announced on 9 October 2025. The repurchased shares will be used to fulfill Fagron's obligations under its long-term incentive scheme.

More information, including a detailed overview of the purchase transactions under this program, is available on our [share buy-back webpage](#).

Financial calendar

12 February 2026

9 April 2026

11 May 2026

30 July 2026

8 October 2026

Full year results 2025

Trading update first quarter 2026

Annual General Meeting 2025

Half year results 2026

Trading update third quarter 2026

Further information

Ignacio Artola

Global Investor Relations Leader

ignacio.artola@fagron.com

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. Fagron's operational activities are managed through the Dutch company Fagron BV. Fagron BV's head office is located in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.